The stock of Oxford-AstraZeneca doses is running out fast but the government, despite frantic efforts to keep the inoculation campaign on track, is yet to secure a contract for bulk supply of alternative Covid-19 vaccines.
The government suspended administration of the first dose on April 26, immediately after the Indian government barred export of Covishield the AstraZeneca vaccine produced by the Serum Institute of India.
The Directorate General of Health Services (DGHS) yesterday said the stock of the Covid-19 vaccine is running out as there are only 14 lakh jabs in stock with no sign of fresh shipment from India.
There will be a vaccine crisis if a fresh consignment does not arrive in the country before the existing stock is exhausted, DGHS spokesperson Dr Robed Amin said.